ABSTRACT
In a multicenter, prospective treatment study, 59 patients with complicated or uncomplicated urinary tract infections (UTIs) were treated with norfloxacin (400 mg orally twice daily) and compared with 45 patients treated with trimethoprim/sulfamethoxazole. Norfloxacin was relatively safe and highly effective in treating both uncomplicated UTIs (86 percent cure rate) and complicated UTIs (75 percent cure rate). Failure of trimethoprim/sulfamethoxazole therapy was associated with initial bacterial resistance, e.g., from Pseudomonas aeruginosa and Serratia marcescens; such multiresistant bacteria were successfully treated with norfloxacin. Thus, norfloxacin appears to extend the range of oral agents available to treat UTIs.
Subject(s)
Norfloxacin/therapeutic use , Urinary Tract Infections/drug therapy , Adult , Aged , Aged, 80 and over , Clinical Trials as Topic , Drug Combinations/adverse effects , Drug Combinations/therapeutic use , Female , Humans , Male , Middle Aged , Norfloxacin/adverse effects , Prospective Studies , Random Allocation , Recurrence , Sulfamethoxazole/adverse effects , Sulfamethoxazole/therapeutic use , Trimethoprim/adverse effects , Trimethoprim/therapeutic use , Trimethoprim, Sulfamethoxazole Drug Combination , Urinary Tract Infections/complicationsABSTRACT
In a prospective, randomized, double-blind trial, ciprofloxacin (250 mg orally, twice daily) was compared with cinoxacin (500 mg orally, twice daily) in 60 patients with urinary tract infections. Most patients were women with uncomplicated urinary tract infections. Escherichia coli was the most common isolate (36 patients). Clinical and microbiologic cure occurred in 20 of 24 (83 percent) evaluable patients treated with ciprofloxacin, compared with 15 of 21 (71 percent) evaluable patients treated with cinoxacin. Ciprofloxacin was well tolerated and had a low incidence of minor side effects that included Candida vaginitis, headache, and gastrointestinal intolerance. Relapse or failed therapy was not associated with the development of resistance.
Subject(s)
Bacterial Infections/drug therapy , Cinoxacin/therapeutic use , Ciprofloxacin/therapeutic use , Pyridazines/therapeutic use , Urinary Tract Infections/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Cinoxacin/adverse effects , Ciprofloxacin/adverse effects , Clinical Trials as Topic , Digestive System/drug effects , Double-Blind Method , Escherichia coli Infections/drug therapy , Female , Gram-Negative Bacteria , Humans , Male , Middle Aged , Random AllocationABSTRACT
In a prospective, randomized trial, norfloxacin (400 mg perorally, twice a day) was compared with trimethoprim-sulfamethoxazole (160-800 mg perorally, twice a day) in 45 patients with uncomplicated urinary tract infections. Escherichia coli was the most common isolate. Infections due to Enterobacter spp., Proteus mirabilis, Pseudomonas spp., and Staphylococcus spp. were also treated. Norfloxacin was equivalent in effectiveness and safety to trimethoprim-sulfamethoxazole, with a cure rate of 91% at the 5- to 9-day posttherapy visit and 88% at the 4- to 6-week posttherapy visit. It was well tolerated and had a low incidence of side effects.
